▶ 調査レポート

経口血糖降下薬(OHA)の世界市場 2020年:メーカー別、地域別、種類・用途別

• 英文タイトル:Global Oral Hypoglyceimic Agents (OHAs) Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。経口血糖降下薬(OHA)の世界市場 2020年:メーカー別、地域別、種類・用途別 / Global Oral Hypoglyceimic Agents (OHAs) Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 / D005-11557資料のイメージです。• レポートコード:D005-11557
• 出版社/出版日:GlobalInfoResearch / 2020年5月
• レポート形態:英文、PDF、102ページ
• 納品方法:Eメール(納期2~3日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User¥372,360 (USD3,480)▷ お問い合わせ
  Multi User¥558,540 (USD5,220)▷ お問い合わせ
  Corporate User¥744,720 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、経口血糖降下薬(OHA)の世界市場を広く調査・分析し、今後の市場展望をまとめております。経口血糖降下薬(OHA)の種類別市場規模(スルホニル尿素、メトホルミン、チアゾリジンジオン、αグルコシダーゼ阻害剤)、用途別市場規模(病院・診療所、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(販売量、市場シェア、製品概要、SWOT分析):Pfizer、Huadong Medicine、Bristol-Myers Squibb、GlaxoSmithKline、Servier、Bayer、Double-Crane Pharmaceutical、Sanofi-Aventis、Novonordisk、Wanbang Biopharmaceuticals、Guangzhou Pharmaceutical
・地域別グローバル市場分析 2015年-2020年
・経口血糖降下薬(OHA)の北米市場(アメリカ、カナダ、メキシコ)
・経口血糖降下薬(OHA)のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・経口血糖降下薬(OHA)のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・経口血糖降下薬(OHA)の南米市場(ブラジル、アルゼンチン)
・経口血糖降下薬(OHA)の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:スルホニル尿素、メトホルミン、チアゾリジンジオン、αグルコシダーゼ阻害剤
・用途別分析:病院・診療所、その他
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論

Market Overview
The global Oral Hypoglyceimic Agents (OHAs) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Oral Hypoglyceimic Agents (OHAs) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Oral Hypoglyceimic Agents (OHAs) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Oral Hypoglyceimic Agents (OHAs) market has been segmented into
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors

By Application, Oral Hypoglyceimic Agents (OHAs) has been segmented into:
Hospitals and Clinics
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Oral Hypoglyceimic Agents (OHAs) market presented in the report. This section sheds light on the sales growth of different regional and country-level Oral Hypoglyceimic Agents (OHAs) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Oral Hypoglyceimic Agents (OHAs) market.

The report offers in-depth assessment of the growth and other aspects of the Oral Hypoglyceimic Agents (OHAs) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Oral Hypoglyceimic Agents (OHAs) Market Share Analysis
Oral Hypoglyceimic Agents (OHAs) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Oral Hypoglyceimic Agents (OHAs) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Oral Hypoglyceimic Agents (OHAs) sales, revenue and market share for each player covered in this report.

The major players covered in Oral Hypoglyceimic Agents (OHAs) are:
Pfizer
Huadong Medicine
Bristol-Myers Squibb
GlaxoSmithKline
Servier
Bayer
Double-Crane Pharmaceutical
Sanofi-Aventis
Novonordisk
Wanbang Biopharmaceuticals
Guangzhou Pharmaceutical

Among other players domestic and global, Oral Hypoglyceimic Agents (OHAs) market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Hypoglyceimic Agents (OHAs) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oral Hypoglyceimic Agents (OHAs), with price, sales, revenue and global market share of Oral Hypoglyceimic Agents (OHAs) in 2018 and 2019.
Chapter 3, the Oral Hypoglyceimic Agents (OHAs) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Hypoglyceimic Agents (OHAs) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Oral Hypoglyceimic Agents (OHAs) market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Oral Hypoglyceimic Agents (OHAs) sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

Table of Contents

1 Market Overview
1.1 Oral Hypoglyceimic Agents (OHAs) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oral Hypoglyceimic Agents (OHAs) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Sulfonylureas
1.2.3 Metformin
1.2.4 Thiazolidinediones
1.2.5 Alpha-Glucosidase Inhibitors
1.3 Market Analysis by Application
1.3.1 Overview: Global Oral Hypoglyceimic Agents (OHAs) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Overview of Global Oral Hypoglyceimic Agents (OHAs) Market
1.4.1 Global Oral Hypoglyceimic Agents (OHAs) Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Huadong Medicine
2.2.1 Huadong Medicine Details
2.2.2 Huadong Medicine Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Huadong Medicine SWOT Analysis
2.2.4 Huadong Medicine Product and Services
2.2.5 Huadong Medicine Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb SWOT Analysis
2.3.4 Bristol-Myers Squibb Product and Services
2.3.5 Bristol-Myers Squibb Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GlaxoSmithKline SWOT Analysis
2.4.4 GlaxoSmithKline Product and Services
2.4.5 GlaxoSmithKline Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Servier
2.5.1 Servier Details
2.5.2 Servier Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Servier SWOT Analysis
2.5.4 Servier Product and Services
2.5.5 Servier Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bayer
2.6.1 Bayer Details
2.6.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Bayer SWOT Analysis
2.6.4 Bayer Product and Services
2.6.5 Bayer Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Double-Crane Pharmaceutical
2.7.1 Double-Crane Pharmaceutical Details
2.7.2 Double-Crane Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Double-Crane Pharmaceutical SWOT Analysis
2.7.4 Double-Crane Pharmaceutical Product and Services
2.7.5 Double-Crane Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Sanofi-Aventis
2.8.1 Sanofi-Aventis Details
2.8.2 Sanofi-Aventis Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Sanofi-Aventis SWOT Analysis
2.8.4 Sanofi-Aventis Product and Services
2.8.5 Sanofi-Aventis Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novonordisk
2.9.1 Novonordisk Details
2.9.2 Novonordisk Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novonordisk SWOT Analysis
2.9.4 Novonordisk Product and Services
2.9.5 Novonordisk Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Wanbang Biopharmaceuticals
2.10.1 Wanbang Biopharmaceuticals Details
2.10.2 Wanbang Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Wanbang Biopharmaceuticals SWOT Analysis
2.10.4 Wanbang Biopharmaceuticals Product and Services
2.10.5 Wanbang Biopharmaceuticals Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Guangzhou Pharmaceutical
2.11.1 Guangzhou Pharmaceutical Details
2.11.2 Guangzhou Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Guangzhou Pharmaceutical SWOT Analysis
2.11.4 Guangzhou Pharmaceutical Product and Services
2.11.5 Guangzhou Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Oral Hypoglyceimic Agents (OHAs) Manufacturer Market Share in 2019
3.3.2 Top 6 Oral Hypoglyceimic Agents (OHAs) Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Market Share by Regions
4.1.1 Global Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Regions (2015-2020)
4.1.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Regions (2015-2020)
4.2 North America Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
4.3 Europe Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
4.5 South America Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Market Share by Country
5.1.1 North America Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Country (2015-2020)
5.1.2 North America Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Country (2015-2020)
5.2 United States Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
5.3 Canada Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
5.4 Mexico Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Market Share by Country
6.1.1 Europe Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Country (2015-2020)
6.1.2 Europe Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Country (2015-2020)
6.2 Germany Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
6.3 UK Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
6.4 France Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
6.5 Russia Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
6.6 Italy Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Regions (2015-2020)
7.2 China Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
7.3 Japan Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
7.4 Korea Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
7.5 India Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
7.7 Australia Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Market Share by Country
8.1.1 South America Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Country (2015-2020)
8.1.2 South America Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Country (2015-2020)
8.2 Brazil Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
8.3 Argentina Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
9.3 Turkey Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
9.4 Egypt Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
9.5 South Africa Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Oral Hypoglyceimic Agents (OHAs) Sales and Market Share by Type (2015-2020)
10.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue and Market Share by Type (2015-2020)
10.3 Global Oral Hypoglyceimic Agents (OHAs) Price by Type (2015-2020)
11 Global Oral Hypoglyceimic Agents (OHAs) Market Segment by Application
11.1 Global Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Application (2015-2020)
11.2 Global Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Application (2015-2020)
11.3 Global Oral Hypoglyceimic Agents (OHAs) Price by Application (2015-2020)
12 Market Forecast
12.1 Global Oral Hypoglyceimic Agents (OHAs) Sales, Revenue and Growth Rate (2021-2025)
12.2 Oral Hypoglyceimic Agents (OHAs) Market Forecast by Regions (2021-2025)
12.2.1 North America Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025)
12.2.2 Europe Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025)
12.2.3 Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025)
12.2.4 South America Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025)
12.2.5 Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025)
12.3 Oral Hypoglyceimic Agents (OHAs) Market Forecast by Type (2021-2025)
12.3.1 Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Type (2021-2025)
12.3.2 Global Oral Hypoglyceimic Agents (OHAs) Market Share Forecast by Type (2021-2025)
12.4 Oral Hypoglyceimic Agents (OHAs) Market Forecast by Application (2021-2025)
12.4.1 Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Application (2021-2025)
12.4.2 Global Oral Hypoglyceimic Agents (OHAs) Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables

Table 1. Global Oral Hypoglyceimic Agents (OHAs) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Oral Hypoglyceimic Agents (OHAs) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Oral Hypoglyceimic Agents (OHAs) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Oral Hypoglyceimic Agents (OHAs) Major Business
Table 9. Pfizer Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 10. Pfizer SWOT Analysis
Table 11. Pfizer Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 12. Pfizer Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 14. Huadong Medicine Oral Hypoglyceimic Agents (OHAs) Major Business
Table 15. Huadong Medicine Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 16. Huadong Medicine SWOT Analysis
Table 17. Huadong Medicine Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 18. Huadong Medicine Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 20. Bristol-Myers Squibb Oral Hypoglyceimic Agents (OHAs) Major Business
Table 21. Bristol-Myers Squibb Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 22. Bristol-Myers Squibb SWOT Analysis
Table 23. Bristol-Myers Squibb Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 24. Bristol-Myers Squibb Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 26. GlaxoSmithKline Oral Hypoglyceimic Agents (OHAs) Major Business
Table 27. GlaxoSmithKline Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 28. GlaxoSmithKline SWOT Analysis
Table 29. GlaxoSmithKline Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 30. GlaxoSmithKline Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Servier Basic Information, Manufacturing Base and Competitors
Table 32. Servier Oral Hypoglyceimic Agents (OHAs) Major Business
Table 33. Servier Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 34. Servier SWOT Analysis
Table 35. Servier Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 36. Servier Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Bayer Basic Information, Manufacturing Base and Competitors
Table 38. Bayer Oral Hypoglyceimic Agents (OHAs) Major Business
Table 39. Bayer Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 40. Bayer SWOT Analysis
Table 41. Bayer Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 42. Bayer Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Double-Crane Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 44. Double-Crane Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Major Business
Table 45. Double-Crane Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 46. Double-Crane Pharmaceutical SWOT Analysis
Table 47. Double-Crane Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 48. Double-Crane Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Sanofi-Aventis Basic Information, Manufacturing Base and Competitors
Table 50. Sanofi-Aventis Oral Hypoglyceimic Agents (OHAs) Major Business
Table 51. Sanofi-Aventis Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 52. Sanofi-Aventis SWOT Analysis
Table 53. Sanofi-Aventis Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 54. Sanofi-Aventis Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Novonordisk Basic Information, Manufacturing Base and Competitors
Table 56. Novonordisk Oral Hypoglyceimic Agents (OHAs) Major Business
Table 57. Novonordisk Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 58. Novonordisk SWOT Analysis
Table 59. Novonordisk Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 60. Novonordisk Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Wanbang Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 62. Wanbang Biopharmaceuticals Oral Hypoglyceimic Agents (OHAs) Major Business
Table 63. Wanbang Biopharmaceuticals Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 64. Wanbang Biopharmaceuticals SWOT Analysis
Table 65. Wanbang Biopharmaceuticals Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 66. Wanbang Biopharmaceuticals Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Guangzhou Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 68. Guangzhou Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Major Business
Table 69. Guangzhou Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Total Revenue (USD Million) (2017-2018)
Table 70. Guangzhou Pharmaceutical SWOT Analysis
Table 71. Guangzhou Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Product and Services
Table 72. Guangzhou Pharmaceutical Oral Hypoglyceimic Agents (OHAs) Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Global Oral Hypoglyceimic Agents (OHAs) Sales by Manufacturer (2018-2019) (K MT)
Table 74. Global Oral Hypoglyceimic Agents (OHAs) Revenue by Manufacturer (2018-2019) (USD Million)
Table 75. Global Oral Hypoglyceimic Agents (OHAs) Sales by Regions (2015-2020) (K MT)
Table 76. Global Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Regions (2015-2020)
Table 77. Global Oral Hypoglyceimic Agents (OHAs) Revenue by Regions (2015-2020) (USD Million)
Table 78. North America Oral Hypoglyceimic Agents (OHAs) Sales by Countries (2015-2020) (K MT)
Table 79. North America Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries (2015-2020)
Table 80. North America Oral Hypoglyceimic Agents (OHAs) Revenue by Countries (2015-2020) (USD Million)
Table 81. North America Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries (2015-2020)
Table 82. Europe Oral Hypoglyceimic Agents (OHAs) Sales by Countries (2015-2020) (K MT)
Table 83. Europe Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries (2015-2020)
Table 84. Europe Oral Hypoglyceimic Agents (OHAs) Revenue by Countries (2015-2020) (USD Million)
Table 85. Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Sales by Regions (2015-2020) (K MT)
Table 86. Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Regions (2015-2020)
Table 87. Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Revenue by Regions (2015-2020) (USD Million)
Table 88. South America Oral Hypoglyceimic Agents (OHAs) Sales by Countries (2015-2020) (K MT)
Table 89. South America Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries (2015-2020)
Table 90. South America Oral Hypoglyceimic Agents (OHAs) Revenue by Countries (2015-2020) (USD Million)
Table 91. South America Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries (2015-2020)
Table 92. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Sales by Countries (2015-2020) (K MT)
Table 93. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries (2015-2020)
Table 94. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Revenue by Countries (2015-2020) (USD Million)
Table 95. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries (2015-2020)
Table 96. Global Oral Hypoglyceimic Agents (OHAs) Sales by Type (2015-2020) (K MT)
Table 97. Global Oral Hypoglyceimic Agents (OHAs) Sales Share by Type (2015-2020)
Table 98. Global Oral Hypoglyceimic Agents (OHAs) Revenue by Type (2015-2020) (USD Million)
Table 99. Global Oral Hypoglyceimic Agents (OHAs) Revenue Share by Type (2015-2020)
Table 100. Global Oral Hypoglyceimic Agents (OHAs) Sales by Application (2015-2020) (K MT)
Table 101. Global Oral Hypoglyceimic Agents (OHAs) Sales Share by Application (2015-2020)
Table 102. Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Regions (2021-2025) (K MT)
Table 103. Global Oral Hypoglyceimic Agents (OHAs) Market Share Forecast by Regions (2021-2025)
Table 104. Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Type (2021-2025) (K MT)
Table 105. Global Oral Hypoglyceimic Agents (OHAs) Market Share Forecast by Type (2021-2025)
Table 106. Global Oral Hypoglyceimic Agents (OHAs) Sales Forecast by Application (2021-2025)
Table 107. Global Oral Hypoglyceimic Agents (OHAs) Market Share Forecast by Application (2021-2025)
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Oral Hypoglyceimic Agents (OHAs) Picture
Figure 2. Global Sales Market Share of Oral Hypoglyceimic Agents (OHAs) by Type in 2019
Figure 3. Sulfonylureas Picture
Figure 4. Metformin Picture
Figure 5. Thiazolidinediones Picture
Figure 6. Alpha-Glucosidase Inhibitors Picture
Figure 7. Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Application in 2018
Figure 8. Hospitals and Clinics Picture
Figure 9. Others Picture
Figure 10. Global Oral Hypoglyceimic Agents (OHAs) Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Oral Hypoglyceimic Agents (OHAs) Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Manufacturer in 2019
Figure 31. Global Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Oral Hypoglyceimic Agents (OHAs) Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Oral Hypoglyceimic Agents (OHAs) Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 36. Global Oral Hypoglyceimic Agents (OHAs) Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Regions (2015-2020)
Figure 38. Global Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Regions in 2018
Figure 39. North America Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
Figure 40. Europe Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
Figure 42. South America Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020)
Figure 44. North America Oral Hypoglyceimic Agents (OHAs) Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries (2015-2020)
Figure 46. North America Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries in 2018
Figure 47. North America Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries in 2018
Figure 49. United States Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 50. Canada Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 51. Mexico Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 52. Europe Oral Hypoglyceimic Agents (OHAs) Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries in 2019
Figure 55. Germany Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 56. UK Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 57. France Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 58. Russia Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 59. Italy Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 60. Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Regions 2019
Figure 63. China Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 64. Japan Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 65. Korea Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 66. India Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 67. Southeast Asia Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 68. South America Oral Hypoglyceimic Agents (OHAs) Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries in 2019
Figure 70. South America Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries in 2019
Figure 71. Brazil Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 72. Argentina Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 73. Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Oral Hypoglyceimic Agents (OHAs) Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 78. Egypt Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 79. Turkey Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 80. South Africa Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2015-2020) (K MT)
Figure 81. Global Oral Hypoglyceimic Agents (OHAs) Sales and Growth Rate (2021-2025) (K MT)
Figure 82. Global Oral Hypoglyceimic Agents (OHAs) Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025) (K MT)
Figure 84. Europe Sales Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025) (K MT)
Figure 85. Asia-Pacific Sales Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025) (K MT)
Figure 86. South America Sales Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025) (K MT)
Figure 87. Middle East & Africa Sales Oral Hypoglyceimic Agents (OHAs) Market Forecast (2021-2025) (K MT)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel